Redeye returns with an update following AlzeCure’s Q4 2025 earnings release. The company prepares its projects for clinical development, with a key focus on initiating a Phase IIa study with NeuroRestore ACD856 in Alzheimer’s patients in 2026, supported by the EIC grant. Additionally, the Orphan Drug Designation (ODD) for Painless ACD440 from the EMA strengthens its positioning for potential partnerships. We make no significant model adjustments and reiterate our valuation range of SEK0.5-13, with a base case of SEK6. In this update, we review the current deal landscape and conclude with an overview of the company and its key pipeline assets.
LÄS MER
